Resources
Resource type key:
-
White Papers -
Videos -
Peer-Reviewed Papers -
Technical Data -
Protocols
Keyword search:
Webinar: Targeting Tumor Metabolic Adaptations in The Metastatic Niche to Improve Therapy Efficacy
In this webinar, we discuss how the IN SITE™ Metastasis Kit can enable researchers to model common metastatic microenvironments. Dr. Evelyn Aranda and Dr. Zeynep Madak-Erdogan discuss how to evaluate anti-cancer therapeutics in physiologically-relevant tumor models, to investigate metabolic changes in hormone-positive breast cancer, and to identify mechanisms of tumor drug resistance. (more…)
Publication: Targeting Metabolic Adaptations in The Breast Cancer-Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy (2022)
Most patients with ER+ metastatic breast cancer (MBC) undergo treatment with the estrogen receptor antagonist fulvestrant (Fulv) as standard-of-care. Yet, among such patients, metastasis in the liver is associated with reduced overall survival compared to other metastasis sites. The factors underlying the reduced responsiveness of liver metastases to ER-targeting agents remain unknown, impeding the development of more effective treatment approaches to improve outcomes for patients with ER+ liver metastases. The objective of this study was to identify how the metabolism–cancer nexus in liver affects the response of metastatic ER+ tumors to Fulv, focusing particularly on tumor-intrinsic metabolic mechanisms arising following Fulv exposure.
Webinar: Transforming Lung Fibrosis Drug Discovery with The IN MATRICO® Human Lung Fibrosis Platform
Lung extracellular matrix (ECM) is implicated in the pathogenesis and progression of lung fibrosis. Current preclinical lung fibrosis models do not incorporate lung ECM, and therefore lack the defining part of the fibrotic lung disease environment. In this webinar, we describe the paradigm shift in drug discovery from ‘in vitro’ to ‘in matrico’, and present our Human Lung Fibrosis platform for disease modeling and compound testing. Leveraging human fibrotic lung ECM and corresponding clinical data, the platform increases the relevance of cell-based assays and enables lung fibrosis modeling with clinical context to accelerate drug development.
Publication: Combined Targeting of Estrogen Receptor Alpha and Exportin 1 in Metastatic Breast Cancers (2020)
The majority of breast cancer specific deaths in women with estrogen receptor positive (ER+) tumors occur due to metastases that are resistant to therapy. There is a critical need for novel therapeutic approaches to achieve tumor regression and/or maintain therapy responsiveness in metastatic ER+ tumors. The objective of this study was to elucidate the role of metabolic pathways that undermine therapy efficacy in ER+ breast cancers.
Webinar: Redefining Cancer Research with IN SITE™ Metastasis Kit
In this webinar we present the IN SITE™ Metastasis Kit, which contains tissue-specific bone, liver, and lung ECMs, as an in-vitro tool that enables physiologically-relevant studies of metastasis as well as accelerates drug development efforts.
Application Note: IN SITE™ Metastasis Kit to Accelerate Anticancer Drug Development
IN SITE™ Metastasis Kit contains bone, liver, and lung ECMs with tissue-specific compositions and mechanics to model colonization of tumor cells in common secondary sites. Recapitulation of site specific microenvironments is key to identify drivers of metastasis and targets for therapeutic intervention.
Publication: Fibrotic Human Lung Extracellular Matrix as a Disease-Specific Substrate for Models of Pulmonary Fibrosis (2019)
Idiopathic Pulmonary Fibrosis (IPF) is an irreversible and uniformly fatal lung disease marked by destruction and scarring of the lung parenchyma and progressive loss of respiratory function. Unfortunately, predictive models of IPF are not available, underscoring the critical need for physiologically relevant in-vitro substrates that enable quantitative and mechanistic studies of human IPF. Here we report the development and characterization of a human pulmonary fibrosis specific cell culture substrate comprised of intact fibrotic lung extracellular matrix that recapitulates the human IPF disease environment in vitro. Altogether, our results demonstrate the applicability of this fibrosis-specific substrate for 3D in-vitro models of IPF and cell-based assays in early-stage drug discovery.